Constitutional mismatch repair deficiency mimicking Lynch syndrome is associated with hypomorphic mismatch repair gene variants.


Journal

NPJ precision oncology
ISSN: 2397-768X
Titre abrégé: NPJ Precis Oncol
Pays: England
ID NLM: 101708166

Informations de publication

Date de publication:
24 May 2024
Historique:
received: 13 10 2023
accepted: 08 05 2024
medline: 25 5 2024
pubmed: 25 5 2024
entrez: 24 5 2024
Statut: epublish

Résumé

Lynch syndrome (LS) and constitutional mismatch repair deficiency (CMMRD) are distinct cancer syndromes caused, respectively, by mono- and bi-allelic germline mismatch repair (MMR) variants. LS predisposes to mainly gastrointestinal and genitourinary cancers in adulthood. CMMRD predisposes to brain, haematological, and LS-spectrum cancers from childhood. Two suspected LS patients with first cancer diagnosis aged 27 or 38 years were found to be homozygous for an MMR (likely) pathogenic variant, MSH6 c.3226C>T (p.(Arg1076Cys)), or variant of uncertain significance (VUS), MLH1 c.306G>A (p.(Glu102=)). MLH1 c.306G>A was shown to cause leaky exon 3 skipping. The apparent genotype-phenotype conflict was resolved by detection of constitutional microsatellite instability in both patients, a hallmark feature of CMMRD. A hypomorphic effect of these and other variants found in additional late onset CMMRD cases, identified by literature review, likely explains a LS-like phenotype. CMMRD testing in carriers of compound heterozygous or homozygous MMR VUS may find similar cases and novel hypomorphic variants. Individualised management of mono- and bi-allelic carriers of hypomorphic MMR variants is needed until we better characterise the associated phenotypes.

Identifiants

pubmed: 38789506
doi: 10.1038/s41698-024-00603-z
pii: 10.1038/s41698-024-00603-z
doi:

Types de publication

Journal Article

Langues

eng

Pagination

119

Subventions

Organisme : Cancer Research UK (CRUK)
ID : C569/A24991

Informations de copyright

© 2024. The Author(s).

Références

Hause, R. J., Pritchard, C. C., Shendure, J. & Salipante, S. J. Classification and characterization of microsatellite instability across 18 cancer types. Nat. Med 22, 1342–1350 (2016).
pubmed: 27694933 doi: 10.1038/nm.4191
Jin, Z. & Sinicrope, F. A. Prognostic and predictive values of mismatch repair deficiency in non-metastatic colorectal cancer. Cancers 13, https://doi.org/10.3390/cancers13020300 (2021).
Win, A. et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. Cancer Epidemiol., Biomark. Prev. 26, 404–412 (2017).
doi: 10.1158/1055-9965.EPI-16-0693
Dominguez-Valentin, M. et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet. Med.: J. Am. Coll. Med. Genet. 22, 15–25 (2020).
doi: 10.1038/s41436-019-0596-9
Suerink, M. et al. Constitutional mismatch repair deficiency as a differential diagnosis of neurofibromatosis type 1: consensus guidelines for testing a child without malignancy. J. Med. Genet. 56, 53–62 (2019).
pubmed: 30415209 doi: 10.1136/jmedgenet-2018-105664
Wimmer, K. et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium ‘care for CMMRD’ (C4CMMRD). J. Med. Genet. 51, 355–365 (2014).
pubmed: 24737826 doi: 10.1136/jmedgenet-2014-102284
Shiran, S. et al. Multiple brain developmental venous anomalies as a marker for constitutional mismatch repair deficiency syndrome. Am. J. Neuroradiol. https://doi.org/10.3174/ajnr.A5766 (2018).
Vasen, H. et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 62, 812–823 (2013).
pubmed: 23408351 doi: 10.1136/gutjnl-2012-304356
Balmana, J., Balaguer, F., Cervantes, A. & Arnold, D. Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. Ann. Oncol. 24, vi73–vi80 (2013).
pubmed: 23813931 doi: 10.1093/annonc/mdt209
Stoffel, E. et al. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. J. Clin. Oncol. 33, 209–217 (2015).
pubmed: 25452455 doi: 10.1200/JCO.2014.58.1322
Monahan, K. J. et al. Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG). Gut 69, 411–444 (2020).
pubmed: 31780574 doi: 10.1136/gutjnl-2019-319915
Seppälä, T. T. et al. European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender. Br. J. Surg. 108, 484–498 (2021).
pubmed: 34043773 pmcid: 10364896 doi: 10.1002/bjs.11902
Vasen, H. et al. Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium “Care for CMMR-D” (C4CMMR-D). J. Med. Genet. 51, 283–293 (2014).
pubmed: 24556086 doi: 10.1136/jmedgenet-2013-102238
Durno, C. et al. Recommendations on surveillance and management of biallelic mismatch repair deficiency (BMMRD) syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Gastrointest. Endosc. 85, 873–882 (2017).
pubmed: 28363411 doi: 10.1016/j.gie.2017.03.015
Tabori, U. et al. Clinical management and tumor surveillance recommendations of inherited mismatch repair deficiency in childhood. Clin. Cancer Res. 23, e32–e37 (2017).
pubmed: 28572265 doi: 10.1158/1078-0432.CCR-17-0574
Durno, C. et al. Survival benefit for individuals with constitutional mismatch repair deficiency undergoing surveillance. J. Clin. Oncol.: J. Am. Soc. Clin. Oncol. 39, 2779–2790 (2021).
doi: 10.1200/JCO.20.02636
Ghorbanoghli, Z. et al. High yield of surveillance in patients diagnosed with constitutional mismatch repair deficiency. J. Med. Genet. 60, 679–684 (2023).
pubmed: 36411031 doi: 10.1136/jmg-2022-108829
Plaschke, J. et al. Compound heterozygosity for two MSH6 mutations in a patient with early onset of HNPCC-associated cancers, but without hematological malignancy and brain tumor. Eur. J. Hum. Genet.: EJHG 14, 561–566 (2006).
pubmed: 16418736 doi: 10.1038/sj.ejhg.5201568
Okkels, H. et al. Polyposis and early cancer in a patient with low penetrant mutations in MSH6 and APC: hereditary colorectal cancer as a polygenic trait. Int. J. colorectal Dis. 21, 847–850 (2006).
pubmed: 16525781 doi: 10.1007/s00384-006-0086-9
Rahner, N. et al. Compound heterozygosity for two MSH6 mutations in a patient with early onset colorectal cancer, vitiligo and systemic lupus erythematosus. Am. J. Med. Genet. Part A 146a, 1314–1319 (2008).
pubmed: 18409202 doi: 10.1002/ajmg.a.32210
Jasperson, K. W., Samowitz, W. S. & Burt, R. W. Constitutional mismatch repair-deficiency syndrome presenting as colonic adenomatous polyposis: clues from the skin. Clin. Genet. 80, 394–397 (2011).
pubmed: 21039432 doi: 10.1111/j.1399-0004.2010.01543.x
Klarskov, L. et al. Challenges in the identification of MSH6-associated colorectal cancer: rectal location, less typical histology, and a subset with retained mismatch repair function. Am. J. Surg. Pathol. 35, 1391–1399 (2011).
pubmed: 21836479 doi: 10.1097/PAS.0b013e318225c3f0
Schofield, L. et al. Population-based detection of Lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test. Int J. Cancer 124, 1097–1102 (2009).
pubmed: 19072991 doi: 10.1002/ijc.23863
Nilbert, M. et al. Major contribution from recurrent alterations and MSH6 mutations in the Danish Lynch syndrome population. Fam. Cancer 8, 75–83 (2009).
pubmed: 18566915 doi: 10.1007/s10689-008-9199-3
Limburg, P. J. et al. Prevalence of alterations in DNA mismatch repair genes in patients with young-onset colorectal cancer. Clin. Gastroenterol. Hepatol.: Clin. Pract. J. Am. Gastroenterolog. Assoc. 9, 497–502 (2011).
doi: 10.1016/j.cgh.2010.10.021
Lagerstedt-Robinson, K. et al. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population. Oncol. Rep. 36, 2823–2835 (2016).
pubmed: 27601186 doi: 10.3892/or.2016.5060
Gallon, R. et al. Constitutional microsatellite instability, genotype, and phenotype correlations in constitutional mismatch repair deficiency. Gastroenterology 164, 579–592.e578 (2023).
pubmed: 36586540 doi: 10.1053/j.gastro.2022.12.017
Aronson, M. et al. Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group. J. Med Genet 59, 318–327 (2022).
pubmed: 33622763 doi: 10.1136/jmedgenet-2020-107627
Shlien, A. et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat. Genet. 47, 257–262 (2015).
pubmed: 25642631 doi: 10.1038/ng.3202
Campbell, B. et al. Comprehensive Analysis of Hypermutation in Human Cancer. Cell 171, 1042–1056.e1010 (2017).
pubmed: 29056344 pmcid: 5849393 doi: 10.1016/j.cell.2017.09.048
Hodel, K. P. et al. POLE mutation spectra are shaped by the mutant allele identity, its abundance, and mismatch repair status. Mol. Cell 78, 1166–1177.e1166 (2020).
pubmed: 32497495 pmcid: 8177757 doi: 10.1016/j.molcel.2020.05.012
Ostroverkhova, D. et al. DNA polymerase ε and δ variants drive mutagenesis in polypurine tracts in human tumors. Cell Rep. 43, 113655 (2024).
pubmed: 38219146 pmcid: 10830898 doi: 10.1016/j.celrep.2023.113655
Palles, C. et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat. Genet 45, 136–144 (2013).
pubmed: 23263490 doi: 10.1038/ng.2503
Sehested, A. et al. Constitutional POLE variants causing a phenotype reminiscent of constitutional mismatch repair deficiency. Hum. Mutat. 43, 85–96 (2022).
pubmed: 34816535 doi: 10.1002/humu.24299
Schamschula, E. et al. Teenage-onset colorectal cancers in a digenic cancer predisposition syndrome provide clues for the interaction between mismatch repair and polymerase δ proofreading deficiency in tumorigenesis. Biomolecules 12, 1350 (2022).
pubmed: 36291559 pmcid: 9599501 doi: 10.3390/biom12101350
Borràs, E. et al. Comprehensive functional assessment of MLH1 variants of unknown significance. Hum. Mutat. 33, 1576–1588 (2012).
pubmed: 22736432 doi: 10.1002/humu.22142
Thompson, B. A., Martins, A. & Spurdle, A. B. A review of mismatch repair gene transcripts: issues for interpretation of mRNA splicing assays. Clin. Genet. 87, 100–108 (2015).
pubmed: 24989436 doi: 10.1111/cge.12450
Gardès, P. et al. Human MSH6 deficiency is associated with impaired antibody maturation. J. Immunol. (Baltim., Md. : 1950) 188, 2023–2029 (2012).
doi: 10.4049/jimmunol.1102984
Lavoine, N. et al. Constitutional mismatch repair deficiency syndrome: clinical description in a French cohort. J. Med. Genet. 52, 770–778 (2015).
pubmed: 26318770 doi: 10.1136/jmedgenet-2015-103299
Li, L. et al. A homozygous PMS2 founder mutation with an attenuated constitutional mismatch repair deficiency phenotype. J. Med. Genet. 52, 348–352 (2015).
pubmed: 25691505 doi: 10.1136/jmedgenet-2014-102934
Shuen, A. et al. Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue. J. Clin. Oncol.: J. Am. Soc. Clin. Oncol. 37, 461–470 (2019).
doi: 10.1200/JCO.18.00474
Xie, T. et al. Heterogeneous constitutional mismatch repair deficiency with MSH6 missense mutation clinically benefits from pembrolizumab and regorafenib combination therapy: a case report and literature review. Hereditary Cancer Clin. Pract. 19, 7 (2021).
doi: 10.1186/s13053-021-00165-2
Bruekner, S. R. et al. Unexpected moves: a conformational change in MutSα enables high-affinity DNA mismatch binding. Nucleic acids Res. 51, 1173–1188 (2023).
pubmed: 36715327 pmcid: 9943660 doi: 10.1093/nar/gkad015
Houlleberghs, H. et al. Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants. Proc. Natl Acad. Sci. USA 113, 4128–4133 (2016).
pubmed: 26951660 pmcid: 4839441 doi: 10.1073/pnas.1520813113
Biswas, K. et al. A novel mouse model of PMS2 founder mutation that causes mismatch repair defect due to aberrant splicing. Cell Death Dis. 12, 838 (2021).
pubmed: 34489406 pmcid: 8421400 doi: 10.1038/s41419-021-04130-8
Zou, X. et al. A systematic CRISPR screen defines mutational mechanisms underpinning signatures caused by replication errors and endogenous DNA damage. Nat. Cancer 2, 643–657 (2021).
pubmed: 34164627 pmcid: 7611045 doi: 10.1038/s43018-021-00200-0
Kets, C. M. et al. Compound heterozygosity for two MSH2 mutations suggests mild consequences of the initiation codon variant c.1A>G of MSH2. Eur. J. Hum. Genet.: EJHG 17, 159–164 (2009).
pubmed: 18781192 doi: 10.1038/ejhg.2008.153
Suraweera, N. et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 123, 1804–1811 (2002).
pubmed: 12454837 doi: 10.1053/gast.2002.37070
Buhard, O., Suraweera, N., Lectard, A., Duval, A. & Hamelin, R. Quasimonomorphic mononucleotide repeats for high-level microsatellite instability analysis. Dis. Markers 20, 251–257 (2004).
pubmed: 15528790 pmcid: 3888729 doi: 10.1155/2004/159347
Thibodeau, S. et al. Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res. 58, 1713–1718 (1998).
pubmed: 9563488
Khandekar, A. et al. Visualizing and exploring patterns of large mutational events with SigProfilerMatrixGenerator. BMC Genomics 24, 469 (2023).
pubmed: 37605126 pmcid: 10440861 doi: 10.1186/s12864-023-09584-y
Islam, S. M. A. et al. Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor. Cell Genom. 2, https://doi.org/10.1016/j.xgen.2022.100179 (2022).
Díaz-Gay, M. et al. Assigning mutational signatures to individual samples and individual somatic mutations with SigProfilerAssignment. Bioinformatics 39, btad756 (2023).
pubmed: 38096571 pmcid: 10746860 doi: 10.1093/bioinformatics/btad756
Pollard, K. S., Hubisz, M. J., Rosenbloom, K. R. & Siepel, A. Detection of nonneutral substitution rates on mammalian phylogenies. Genome Res 20, 110–121 (2010).
pubmed: 19858363 pmcid: 2798823 doi: 10.1101/gr.097857.109
Jaganathan, K. et al. Predicting splicing from primary sequence with deep learning. Cell 176, 535–548.e24 (2019).
pubmed: 30661751 doi: 10.1016/j.cell.2018.12.015
Ioannidis, N. M. et al. REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. Am. J. Hum. Genet 99, 877–885 (2016).
pubmed: 27666373 pmcid: 5065685 doi: 10.1016/j.ajhg.2016.08.016
Cheng, J. et al. Accurate proteome-wide missense variant effect prediction with AlphaMissense. Science 381, eadg7492 (2023).
pubmed: 37733863 doi: 10.1126/science.adg7492
Ingham, D. et al. Simple detection of germline microsatellite instability for diagnosis of constitutional mismatch repair cancer syndrome. Hum. Mutat. 34, 847–852 (2013).
pubmed: 23483711 doi: 10.1002/humu.22311
Gallon, R. et al. A sensitive and scalable microsatellite instability assay to diagnose constitutional mismatch repair deficiency by sequencing of peripheral blood leukocytes. Hum. Mutat. 40, 649–655 (2019).
pubmed: 30740824 pmcid: 6519362 doi: 10.1002/humu.23721
Bodo, S. et al. Diagnosis of constitutional mismatch repair-deficiency syndrome based on microsatellite instability and lymphocyte tolerance to methylating agents. Gastroenterology 149, 1017–1029 (2015).
pubmed: 26116798 doi: 10.1053/j.gastro.2015.06.013
Etzler, J. et al. RNA-based mutation analysis identifies an unusual MSH6 splicing defect and circumvents PMS2 pseudogene interference. Hum. Mutat. 29, 299–305 (2008).
pubmed: 18030674 doi: 10.1002/humu.20657
Ryan, K. J. & Cooper, T. A. Muscle-specific splicing enhancers regulate inclusion of the cardiac troponin T alternative exon in embryonic skeletal muscle. Mol. Cell. Biol. 16, 4014–4023 (1996).
pubmed: 8754799 pmcid: 231397 doi: 10.1128/MCB.16.8.4014

Auteurs

Richard Gallon (R)

Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK. richard.gallon@newcastle.ac.uk.

Carlijn Brekelmans (C)

Centre for Human Genetics, University Hospital Leuven, Leuven, Belgium.

Marie Martin (M)

CHU, University of Liège, Liège, Belgium.

Vincent Bours (V)

CHU, University of Liège, Liège, Belgium.

Esther Schamschula (E)

Institute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.

Albert Amberger (A)

Institute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.

Martine Muleris (M)

Département de Génétique, AP-HP.Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France.
Inserm UMRS_938, Sorbonne Université, Centre de Recherche Saint Antoine, Paris, France.

Chrystelle Colas (C)

Département de Génétique, Institut Curie, Paris, France.
INSERM U830, Université de Paris, Paris, France.

Jeroen Dekervel (J)

Department of Digestive Oncology, University Hospital Leuven, Leuven, Belgium.

Gert De Hertogh (G)

Department of Pathology, University Hospital Leuven, Leuven, Belgium.

Jérôme Coupier (J)

Human Genetics, CHU Liège, Liège, Belgium.

Orphal Colleye (O)

Department of Pathology, CHU Liège, Liège, Belgium.

Edith Sepulchre (E)

CHU, University of Liège, Liège, Belgium.

John Burn (J)

Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Hilde Brems (H)

Centre for Human Genetics, University Hospital Leuven, Leuven, Belgium.

Eric Legius (E)

Centre for Human Genetics, University Hospital Leuven, Leuven, Belgium.

Katharina Wimmer (K)

Institute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria. katharina.wimmer@i-med.ac.at.

Classifications MeSH